ANTONIO ALCI BARONE
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Evaluation of inflammatory activity on liver biopsy of patients with chronic hepatitis C who have recovered from HBV infection: a case series study(2012) LISBOA NETO, G.; CAVALHEIRO, N.; BARONE, A.bookPart Hepatite Aguda e Hepatite Fulminante(2013) BARONE, Antonio Alci- Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients(2011) ARAUJO, E. S. A.; DAHARI, H.; NEUMANN, A. U.; CAVALHEIRO, N. de Paula; MELO, C. E.; MELO, E. S. de; LAYDEN, T. J.; COTLER, S. J.; BARONE, A. A.The objective of this study was to find very early viral kinetic markers to predict nonresponse to hepatitis C virus (HCV) therapy in a group of human immunodeficiency virus (HIV)/HCV-coinfected patients. Twenty-six patients (15 HCV genotype-1 and 11 genotype-3) were treated with a 48-week regimen of peginterferon-alfa-2a (PEG-IFN) (180 mu g/week) and weight-based ribavirin (11 mg/kg/day). Samples were collected at baseline; 4, 8, 12, 18, 24, 30, 36 and 42 h; days 2, 3, 4, 7, 8, 15, 22, 29, 43 and 57 then weekly and monthly. Five patients discontinued treatment. Seven patients (27%) achieved a sustained virological response (SVR). Nadir HCV RNA levels were observed 1.6 +/- 0.3 days after initiation of therapy, followed by a 0.3- to 12.9-fold viral rebound until the administration of the second dose of PEG-IFN, which were not associated with SVR or HCV genotype. A viral decline < 1.19 log for genotype-1 and < 0.97 log for genotype-3, 2 days after starting therapy, had a negative predictive value (NPV) of 100% for SVR. The day 2 virological response had a similar positive predictive value for SVR as a rapid virological response at week 4. In addition, a second-phase viral decline slope (i.e., measured from day 2 to 29) < 0.3 log/week had a NPV = 100% for SVR. We conclude that first-phase viral decline at day 2 and second-phase viral decline slope (< 0.3 log/week) are excellent predictors of nonresponse. Further studies are needed to validate these viral kinetic parameters as early on-treatment prognosticators of nonresponse in patients with HCV and HIV.
bookPart Imunopatogênese da hepatite C(2015) BARONE, Antonio Alci- Hepatitis E virus seroprevalence in patients with chronic hepatitis C at a university hospital in Brazil(2020) MAGRI, Mariana Cavalheiro; MANCHIERO, Caroline; DANTAS, Bianca Peixoto; NUNES, Arielle Karen da Silva; FIGUEIREDO, Gerusa Maria; BARONE, Antonio Alci; TENGAN, Fatima MitikoAim: We investigated the prevalence of anti-hepatitis E virus (HEV) antibodies in patients with chronic hepatitis C and the relationship with liver injury stage. Materials & methods: In total, 451 patients were included and the presence of anti-HEV antibodies was evaluated by ELISA. Results: Anti-HEV IgG antibodies were detected in 45 (10.0%) patients and anti-HEV IgM were detected in two IgG-positive patients (4.4%). The distributions of liver fibrosis, steatosis, inflammatory activity, homeostasis model assessment of insulin resistance and liver enzyme levels were similar between HEV-positive and HEV-negative patients. However, HEV-positive patients had a higher mean age (p = 0.030). The seroprevalence by age group increased from 2.2 (18-30 years) to 53.3% (>60 years). HEV infection was not related to advanced fibrosis. Conclusion: This investigation showed that the seroprevalence of HEV among patients with chronic hepatitis C is similar to that of blood donors in the same region.
- Pharmacodynamics of PEG-IFN-alpha-2a and HCV Response as a Function of IL28B Polymorphism in HIV/HCV-Coinfected Patients(2011) ARAUJO, Evaldo Stanislau Affonso de; DAHARI, Harel; COTLER, Scott J.; LAYDEN, Thomas J.; NEUMANN, Avidan U.; MELO, Carlos Eduardo; BARONE, Antonio AlciWe examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America. Twenty-six subjects received pegylated interferon alpha-2a + ribavirin. Serum HCV-RNA and interferon concentrations were measured frequently during the first 12 weeks of therapy and analyzed using mathematical models. African Americans and whites had a similar distribution of IL28B genotypes (P = 0.5). The IL28B CC genotype was overrepresented (P = 0.015) in patients infected with HCV genotype-3 compared with genotype-1. In both genotype-1 and genotype-3, the first-phase viral decline and the average pegylated interferon-alpha-2a effectiveness during the first week of therapy were larger (trend P <= 0.12) in genotype-CC compared with genotypes-TC/TT. In genotype-1 patients, the second slower phase of viral decline (days 2-29) and infected cells loss rate, delta, were larger (P = 0.02 and 0.11, respectively) in genotype-CC than in genotypes-TC/TT. These associations were not observed in genotype-3 patients.
bookPart Toxoplasmose(2013) BARONE, Antonio Alci; AMATO NETO, VicentebookPart Infecção Hospitalar(2016) LEVIN, Anna Sara; OLIVEIRA, Maura Salaroli de; BARONE, Antonio AlciconferenceObject Lack of association between SOCS3 rs4969170 and interleukin 28B genes with therapeutic response in Brazilian HCV carriers treated with PEG-IFN/RBV(2012) MELO, Carlos E.; ARAUJO, Evaldo S.; MANCHIERO, Caroline; MARTINS, Luciane P.; TENGAN, Fatima M.; BARONE, Antonio A.Chronic HCV infections are related with the production of inappropriate cytokine levels in inflammatory and immune response. IFN-α must activate a signal transduction cascade that involves different intracellular proteins driving interferon-inducible genes to be activated. The proteins suppressor of cytokine signaling (SOCS) represents the main cellular mechanism for cytokine (such as IL10 and IFN) negative regulation. Immune responses may be associated with SOCS3 production driven by therapy against HCV and it seems to be regulated by single nucleotide polymorphisms (SNPs) within SOCS3 gene. Recently, genome-wide association studies have linked response to PEG-IFN/RBV therapy with SNPs near the IL28B gene (rs12979860), encoding for interferon-lambda-3 (IL28B). The rs12979860 CC genotype is associated with a greater rate of sustained virological response (SVR) than the CT or TT genotypes in different HCV patients populations. In this study, we evaluated the frequencies of SOCS3 and IL28B polymorphisms genes and their association with the response to IFN based antiviral therapy in chronic hepatitis C infection. After IRB ethics approval, frozen samples from 142 HCV Genotype-1 infected Brazilian patients were analyzed. Genomic DNA from patients classified as responders (R=71) and nonresponders (NR=71) to a PEG-IFN/RBV therapy were used in this study. The SNPs near the IL28B (rs12979860) and SOCS3 (rs4969170) genes were examined using an assay with allele specific PCR probes. According recent publications, IL28B CC genotype was considered the more favorable profile to reach Sustained Virologic Response (SVR). Regarding SOCS3 AA genotype was also recently strongly associated with failure of the IFN-α based therapy. The results are summarized in the table 1. As expected IL28B CC SNP was associated with a better response to antiviral therapy. Conversely, we could not observe a clear association between the polymorphism rs4969170 SOCS3 gene and lack of response to IFN based therapy in our population. Therefore we conclude that the SOCS3 rs4969170 was not as good as IL28B on predicting therapy outcome for HCV.- Prevalence of multidrug-resistant tuberculosis in Latin America and the Caribbean: a systematic review and meta-analysis(2020) TENGAN, Fatima M.; FIGUEIREDO, Gerusa M.; LEITE, Olavo H. M.; NUNES, Arielle K. S.; MANCHIERO, Carol; DANTAS, Bianca P.; MAGRI, Mariana C.; BARONE, Antonio A.; BERNARDO, Wanderley M.Objectives To evaluate the prevalence of multidrug-resistant tuberculosis (MDR-TB) in individuals living in Latin America and the Caribbean (LAC). Methods We searched the MEDLINE, Embase and Literatura Latino Americana e do Caribe em Ciencias da Saude (Lilacs) databases until 08 August 2019 for all studies on the subject, without time or language restrictions. Original studies reporting the prevalence of infection withMycobacterium tuberculosisresistant to isoniazid and rifampicin simultaneously (MDR) in LAC, the prevalence of resistance in cases with no previous treatment (new cases) and the prevalence of resistance in previously treated cases were selected. Considering the expected heterogeneity between studies, all analyses were performed using the random effects model, and heterogeneity was assessed using the I(2)statistic. Results We included 91 studies from 16 countries. The estimated overall prevalence was 13.0% (95% CI 12.0-14.0%), and the heterogeneity between studies was substantial (I-2 = 96.1%). In the subgroup analyses, it was observed that the prevalence of MDR-TB among new cases was 7.0% (95% CI 6.0-7.0%) and in previously treated cases was 26.0% (95% CI 24.0-28.0%). Conclusions This review highlights multidrug resistance to antituberculosis drugs in LAC, indicating that prevention strategies have not been effective. Government institutions should invest heavily in strategies for early diagnosis and the rapid availability of effective treatments and prioritise adequate protection for health professionals. In addition, screening programmes should be adopted to prevent secondary cases.